Limits...
TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity.

Agarwal JJ, Zhu Y, Zhang QY, Mongin AA, Hough LB - PLoS ONE (2013)

Bottom Line: However, previously published work has only characterized the effects of TRAM-34 on a single CYP isoform.TRAM-34 also had both stimulatory and inhibitory effects on human CYP3A4 activity, depending on the substrate used.These results show that low micromolar concentrations of TRAM-34 can inhibit several rat and human CYP isoforms, and suggest caution in the use of high concentrations of this drug as a selective IKCa channel blocker.

View Article: PubMed Central - PubMed

Affiliation: Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York, United States of America.

ABSTRACT
TRAM-34, a clotrimazole analog characterized as a potent and selective inhibitor of intermediate-conductance, calcium-activated K(+) (IKCa) channels, has been used extensively in vitro and in vivo to study the biological roles of these channels. The major advantage of TRAM-34 over clotrimazole is the reported lack of inhibition of the former drug on cytochrome P450 (CYP) activity. CYPs, a large family of heme-containing oxidases, play essential roles in endogenous signaling and metabolic pathways, as well as in xenobiotic metabolism. However, previously published work has only characterized the effects of TRAM-34 on a single CYP isoform. To test the hypothesis that TRAM-34 may inhibit some CYP isoforms, the effects of this compound were presently studied on the activities of four rat and five human CYP isoforms. TRAM-34 inhibited recombinant rat CYP2B1, CYP2C6 and CYP2C11 and human CYP2B6, CYP2C19 and CYP3A4 with IC50 values ranging from 0.9 µM to 12.6 µM, but had no inhibitory effects (up to 80 µM) on recombinant rat CYP1A2, human CYP1A2, or human CYP19A1. TRAM-34 also had both stimulatory and inhibitory effects on human CYP3A4 activity, depending on the substrate used. These results show that low micromolar concentrations of TRAM-34 can inhibit several rat and human CYP isoforms, and suggest caution in the use of high concentrations of this drug as a selective IKCa channel blocker. In addition, in vivo use of TRAM-34 could lead to CYP-related drug-drug interactions.

Show MeSH

Related in: MedlinePlus

Concentration-dependent inhibition of CYP3A4 by TRAM-34 with LVS as substrate.Recombinant enzyme CYP3A4, LVS and varying concentrations of TRAM-34 were incubated according to the methods described. Percent control enzyme activity (ordinate) is plotted versus the log of inhibitor concentration (abscissa). The formation of two LVS metabolites (in brackets) by CYP3A4 is shown. All TRAM-34 data points represent the mean ± SEM of 3 experiments performed in duplicate. The TRAM-34 IC50 values were determined by non-linear regression and are shown in parentheses. Ketoconazole (10 µM) inhibited the formation of both metabolites by greater than 85% (not shown).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3646888&req=5

pone-0063028-g004: Concentration-dependent inhibition of CYP3A4 by TRAM-34 with LVS as substrate.Recombinant enzyme CYP3A4, LVS and varying concentrations of TRAM-34 were incubated according to the methods described. Percent control enzyme activity (ordinate) is plotted versus the log of inhibitor concentration (abscissa). The formation of two LVS metabolites (in brackets) by CYP3A4 is shown. All TRAM-34 data points represent the mean ± SEM of 3 experiments performed in duplicate. The TRAM-34 IC50 values were determined by non-linear regression and are shown in parentheses. Ketoconazole (10 µM) inhibited the formation of both metabolites by greater than 85% (not shown).

Mentions: CYP3A4 activity was further monitored with the clinically-relevant substrate LVS, an anti-hypercholesterolemia drug (Fig. 4). TRAM-34 demonstrated concentration-dependent inhibition of the formation of two major lovastatin metabolites, 6′β-hydroxy LVS and 6′-exomethylene LVS, with IC50 values approximately 1 µM.


TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity.

Agarwal JJ, Zhu Y, Zhang QY, Mongin AA, Hough LB - PLoS ONE (2013)

Concentration-dependent inhibition of CYP3A4 by TRAM-34 with LVS as substrate.Recombinant enzyme CYP3A4, LVS and varying concentrations of TRAM-34 were incubated according to the methods described. Percent control enzyme activity (ordinate) is plotted versus the log of inhibitor concentration (abscissa). The formation of two LVS metabolites (in brackets) by CYP3A4 is shown. All TRAM-34 data points represent the mean ± SEM of 3 experiments performed in duplicate. The TRAM-34 IC50 values were determined by non-linear regression and are shown in parentheses. Ketoconazole (10 µM) inhibited the formation of both metabolites by greater than 85% (not shown).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3646888&req=5

pone-0063028-g004: Concentration-dependent inhibition of CYP3A4 by TRAM-34 with LVS as substrate.Recombinant enzyme CYP3A4, LVS and varying concentrations of TRAM-34 were incubated according to the methods described. Percent control enzyme activity (ordinate) is plotted versus the log of inhibitor concentration (abscissa). The formation of two LVS metabolites (in brackets) by CYP3A4 is shown. All TRAM-34 data points represent the mean ± SEM of 3 experiments performed in duplicate. The TRAM-34 IC50 values were determined by non-linear regression and are shown in parentheses. Ketoconazole (10 µM) inhibited the formation of both metabolites by greater than 85% (not shown).
Mentions: CYP3A4 activity was further monitored with the clinically-relevant substrate LVS, an anti-hypercholesterolemia drug (Fig. 4). TRAM-34 demonstrated concentration-dependent inhibition of the formation of two major lovastatin metabolites, 6′β-hydroxy LVS and 6′-exomethylene LVS, with IC50 values approximately 1 µM.

Bottom Line: However, previously published work has only characterized the effects of TRAM-34 on a single CYP isoform.TRAM-34 also had both stimulatory and inhibitory effects on human CYP3A4 activity, depending on the substrate used.These results show that low micromolar concentrations of TRAM-34 can inhibit several rat and human CYP isoforms, and suggest caution in the use of high concentrations of this drug as a selective IKCa channel blocker.

View Article: PubMed Central - PubMed

Affiliation: Center for Neuropharmacology and Neuroscience, Albany Medical College, Albany, New York, United States of America.

ABSTRACT
TRAM-34, a clotrimazole analog characterized as a potent and selective inhibitor of intermediate-conductance, calcium-activated K(+) (IKCa) channels, has been used extensively in vitro and in vivo to study the biological roles of these channels. The major advantage of TRAM-34 over clotrimazole is the reported lack of inhibition of the former drug on cytochrome P450 (CYP) activity. CYPs, a large family of heme-containing oxidases, play essential roles in endogenous signaling and metabolic pathways, as well as in xenobiotic metabolism. However, previously published work has only characterized the effects of TRAM-34 on a single CYP isoform. To test the hypothesis that TRAM-34 may inhibit some CYP isoforms, the effects of this compound were presently studied on the activities of four rat and five human CYP isoforms. TRAM-34 inhibited recombinant rat CYP2B1, CYP2C6 and CYP2C11 and human CYP2B6, CYP2C19 and CYP3A4 with IC50 values ranging from 0.9 µM to 12.6 µM, but had no inhibitory effects (up to 80 µM) on recombinant rat CYP1A2, human CYP1A2, or human CYP19A1. TRAM-34 also had both stimulatory and inhibitory effects on human CYP3A4 activity, depending on the substrate used. These results show that low micromolar concentrations of TRAM-34 can inhibit several rat and human CYP isoforms, and suggest caution in the use of high concentrations of this drug as a selective IKCa channel blocker. In addition, in vivo use of TRAM-34 could lead to CYP-related drug-drug interactions.

Show MeSH
Related in: MedlinePlus